Design and Rationale of MYOFLAME-19 RCT: MYOcardial protection to reduce inFLAMmatory heart disease due to COVID-19 Infection using CMR Endpoints

• Published in: Journal of cardiovascular magnetic resonance p. 101121
• Main Authors: Puntmann, Valentina O., Beitzke, Dietrich, Kammerlander, Andreas, Voges, Inga, Gabbert, Dominik D., Doerr, Marcus, Chamling, Bishwas, Bozkurt, Biykem, Kaski, Juan Carlos, Spatz, Erica, Herrmann, Eva, Rohde, Gernot, DeLeuw, Philipp, Taylor, Lenka, Windemuth-Kieselbach, Christine, Harz, Cornelia, Santiuste, Marta, Schoeckel, Laura, Hirayama, Juliana, Taylor, Peter C, Berry, Colin, Nagel, Eike
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 29.10.2024
• Subjects: cardiac magnetic resonance; clinical trial; COVID-19; imaging endpoint; microvascular; myocardial inflammation; PP; CRO; CVS; RCT; CPET; W2, W6, W16; CTIS; DSMC; ITT; LVEF; BASG; COVID-19; CSF; WOCBP; EMA; imaging endpoint; CA; clinical trial; microvascular; PASC; ECG; BfARm; CMR; VO2 max; LGE; IMP; PWV; CVD; ACS; myocardial inflammation; AT; IIR; cardiac magnetic resonance; GDPR; HF
• ISSN: 1097-6647; 1532-429X; 1532-429X
• DOI: 10.1016/j.jocmr.2024.101121

Cardiac symptoms due to postacute inflammatory cardiac involvement affect a broad segment of previously well people with only mild acute COVID-19 illness and without overt structural heart disease. Cardiac magnetic resonance (CMR) imaging can identify the underlying subclinical disease process, which is associated with chronic cardiac symptoms. Specific therapy directed at reducing postacute cardiac inflammatory involvement prior to development of myocardial injury and impairment is missing. Prospective multicentre randomised placebo-controlled study of myocardial protection therapy (combined immunosuppressive/antiremodelling) of low-dose prednisolone and losartan. Consecutive symptomatic individuals with a prior COVID-19 infection, no preexisting significant comorbidities or structural heart disease, undergo standardised assessments with questionnaires, CMR imaging and cardiopulmonary exercise testing (CPET). Eligible participants fulfilling the criteria of subclinical Post-COVID inflammatory involvement on baseline CMR examination are randomised to treatment with either verum or placebo for a total of 16 weeks (W16). Participants and investigators remain blinded to the group allocation throughout the study duration. The primary efficacy endpoint is the absolute change of left ventricular ejection fraction (LVEF) to baseline at W16, measured by CMR, between the verum treatment and placebo group by absolute difference, using unpaired t-test confirmatively at the 5% significance level. Secondary endpoints include assessment of changes of symptoms, CMR parameters, and CPET after W16, and frequency of major adverse cardiac events after 1 year. Safety data will be analysed for frequency, severity and types of adverse events (AEs) for all treatment groups. The proportion of AEs related to the contrast agent gadobutrol will also be analysed. A calculated sample size is a total of 280 participants (accounting for 8% drop-out), randomised in 1:1 fashion to 140 in the verum and 140 placebo group. Myoflame-19 study will examine the efficacy of a myocardial protection therapy in symptomatic participants with post-COVID inflammatory cardiac involvement determined by CMR. The aim of the intervention is to reduce the symptoms and inflammatory myocardial injury, to improve exercise tolerance and preclude the development of cardiac impairment. Clinical Trial identifier: NCT05619653 [Display omitted]